Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Original Submission
11 Sep 2021 Submitted Original manuscript
3 Nov 2021 Reviewed Reviewer Report
7 Nov 2021 Reviewed Reviewer Report
22 Nov 2021 Author responded Author comments - Khosro Keshavarz
Resubmission - Version 2
22 Nov 2021 Submitted Manuscript version 2
3 Dec 2021 Reviewed Reviewer Report
5 Dec 2021 Reviewed Reviewer Report
18 Dec 2021 Author responded Author comments - Khosro Keshavarz
Resubmission - Version 3
18 Dec 2021 Submitted Manuscript version 3
12 Jan 2022 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
13 Jan 2022 Editorially accepted
28 Jan 2022 Article published 10.1186/s12913-022-07495-4

You can find further information about peer review here.

Back to article page